Human Health Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Human Health Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	19.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

We Think Human Health Holdings Limited's (HKG:1419) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 25

Market Participants Recognise Human Health Holdings Limited's (HKG:1419) Revenues

Sep 13

Human Health Holdings Limited's (HKG:1419) Share Price Is Matching Sentiment Around Its Earnings

Jan 23

Human Health Holdings (HKG:1419) Seems To Use Debt Quite Sensibly

Mar 21

Shareholders May Be More Conservative With Human Health Holdings Limited's (HKG:1419) CEO Compensation For Now

Nov 26

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Human Health Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:1419 - Analysts future estimates and past financials data (HKD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	591	24	-26	13	N/A
3/31/2024	603	-22	36	93	N/A
12/31/2023	616	-67	98	172	N/A
9/30/2023	809	57	339	418	N/A
6/30/2023	1,002	181	580	664	N/A
3/31/2023	1,208	367	500	566	N/A
12/31/2022	1,415	553	420	468	N/A
9/30/2022	1,268	464	320	382	N/A
6/30/2022	1,122	375	219	296	N/A
3/31/2022	967	297	232	309	N/A
12/31/2021	813	218	245	322	N/A
9/30/2021	734	181	158	204	N/A
6/30/2021	655	144	71	85	N/A
3/31/2021	542	59	65	76	N/A
12/31/2020	430	-27	59	67	N/A
9/30/2020	442	-33	43	52	N/A
6/30/2020	454	-40	26	37	N/A
3/31/2020	492	-11	29	40	N/A
12/31/2019	530	19	33	42	N/A
9/30/2019	529	23	37	46	N/A
6/30/2019	529	27	42	51	N/A
3/31/2019	523	26	47	56	N/A
12/31/2018	518	25	51	62	N/A
9/30/2018	518	24	45	55	N/A
6/30/2018	518	24	38	47	N/A
3/31/2018	509	22	N/A	45	N/A
12/31/2017	501	19	N/A	42	N/A
9/30/2017	491	16	N/A	32	N/A
6/30/2017	481	13	N/A	22	N/A
3/31/2017	493	16	N/A	22	N/A
12/31/2016	504	19	N/A	22	N/A
9/30/2016	505	21	N/A	21	N/A
6/30/2016	499	23	N/A	21	N/A
9/30/2015	456	36	N/A	44	N/A
6/30/2015	430	34	N/A	55	N/A
6/30/2014	365	39	N/A	41	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1419's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 1419's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 1419's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1419's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 1419's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1419's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 02:58
End of Day Share Price	2024/12/23 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Human Health Holdings Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bo Li	BOCOM International Securities Limited

Human Health Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Human Health Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2024

Human Health Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2022

Human Health Holdings Limited Provides Unaudited Financial Guidance for the Six Months Ended December 31, 2021

Recent updates

High number of new directors

Human Health Holdings Limited Announces Executive and Committee Changes

Upcoming dividend of HK$0.028 per share

We Think Human Health Holdings Limited's (HKG:1419) CEO Compensation Package Needs To Be Put Under A Microscope

Full year 2024 earnings released: EPS: HK$0.064 (vs HK$0.48 in FY 2023)

Human Health Holdings Limited Announces Board and Committee Changes

Human Health Holdings Limited, Annual General Meeting, Dec 02, 2024

Market Participants Recognise Human Health Holdings Limited's (HKG:1419) Revenues

Human Health Holdings Limited to Report Q4, 2024 Results on Sep 25, 2024

Human Health Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2024

First half 2024 earnings released: EPS: HK$0.053 (vs HK$0.71 in 1H 2023)

Human Health Holdings Limited to Report First Half, 2024 Results on Feb 27, 2024

Human Health Holdings Limited's (HKG:1419) Share Price Is Matching Sentiment Around Its Earnings

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 16%

Upcoming dividend of HK$0.16 per share at 12% yield

Human Health Holdings Limited, Annual General Meeting, Dec 07, 2023

New minor risk - Profit margin trend

Human Health Holdings Limited Proposes Final Dividend for the Year Ended June 30, 2023, Payable on 29 December 2023

Human Health Holdings Limited to Report Fiscal Year 2023 Results on Sep 26, 2023

First half 2023 earnings released: EPS: HK$0.71 (vs HK$0.24 in 1H 2022)

First half 2023 earnings released: EPS: HK$0.71 (vs HK$0.24 in 1H 2022)

Human Health Holdings Limited to Report First Half, 2023 Results on Feb 24, 2023

Investor sentiment improved over the past week

Upcoming dividend of HK$0.30 per share

Less than half of directors are independent

Full year 2022 earnings released: EPS: HK$0.99 (vs HK$0.38 in FY 2021)

Full year 2022 earnings released: EPS: HK$0.99 (vs HK$0.38 in FY 2021)

Human Health Holdings Limited, Annual General Meeting, Dec 02, 2022

Investor sentiment improved over the past week

Human Health Holdings Limited to Report Fiscal Year 2022 Results on Sep 29, 2022

Human Health Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2022

Less than half of directors are independent

Investor sentiment improved over the past week

Human Health Holdings (HKG:1419) Seems To Use Debt Quite Sensibly

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Human Health Holdings Limited to Report First Half, 2022 Results on Feb 25, 2022

Human Health Holdings Limited Provides Unaudited Financial Guidance for the Six Months Ended December 31, 2021

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.12 per share

Shareholders May Be More Conservative With Human Health Holdings Limited's (HKG:1419) CEO Compensation For Now

Full year 2021 earnings released: EPS HK$0.38 (vs HK$0.11 loss in FY 2020)

Full year 2021 earnings released: EPS HK$0.38 (vs HK$0.11 loss in FY 2020)

Is Human Health Holdings (HKG:1419) Using Too Much Debt?

First half 2021 earnings released: EPS HK$0.045 (vs HK$0.008 in 1H 2020)

Estimating The Fair Value Of Human Health Holdings Limited (HKG:1419)

Human Health Holdings Limited to Report First Half, 2021 Results on Feb 24, 2021

New 90-day high: HK$0.68

Is Human Health Holdings (HKG:1419) Weighed On By Its Debt Load?

New 90-day low: HK$0.55

New 90-day low: HK$0.58

New 90-day low: HK$0.60

Human Health Holdings Limited Resolves Not to Declare Any Final Dividend for Financial Year 2020

Full year earnings released - HK$0.11 loss per share

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources